Literature DB >> 2669751

Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate.

B K Choy1, G A McClarty, J A Wright.   

Abstract

A rapid elevation of ribonucleotide reductase activity was observed with BALB/c 3T3 fibroblasts within 1/2 to 1 hour treatment with 0.1 microM 12-O-tetradecanoylphorbol-13-acetate (TPA). This increase in activity was transient, and returned to about normal levels within 24 to 48 hours. Northern analysis of the two components of ribonucleotide reductase showed a slight transient elevation of M1 mRNA and a marked transient elevation of M2 mRNA after 1/2 hour TPA treatment. As a positive control, ornithine decarboxylase message levels were also observed to be transiently elevated following identical treatment with TPA. Western blot analysis with M1 and M2 specific monoclonal antibodies indicated that the increase in ribonucleotide reductase activity was primarily due to the transient elevation of the M2 but not the M1 protein during treatment with 0.1 microM TPA. This first demonstration that the tumor promotor, TPA, can cause rapid and transient alterations in ribonucleotide reductase suggests that the enzyme, particularly the M2 component, may play an important role in the critical events involved in the process of tumor promotion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669751     DOI: 10.1016/0006-291x(89)90832-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  A novel transforming growth factor-beta 1 responsive cytoplasmic trans-acting factor binds selectively to the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability.

Authors:  F M Amara; F Y Chen; J A Wright
Journal:  Nucleic Acids Res       Date:  1993-10-11       Impact factor: 16.971

2.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.

Authors:  B S Zhou; P Tsai; R Ker; J Tsai; R Ho; J Yu; J Shih; Y Yen
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 4.510

3.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Authors:  Stephen I Shibata; James H Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim A Margolin; Robert J Morgan; George Somlo; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

4.  Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region.

Authors:  F Y Chen; F M Amara; J A Wright
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

5.  Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility.

Authors:  C Hardwick; K Hoare; R Owens; H P Hohn; M Hook; D Moore; V Cripps; L Austen; D M Nance; E A Turley
Journal:  J Cell Biol       Date:  1992-06       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.